Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Leveraging single-cell co-culture and gene expression profiling to identify tumor antigen-specific T cells in oral cancer

Award Number: R01DE034360
ORGANIZATION: NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 04/01/2025
PERIOD OF PERFORMANCE END DATE: 03/31/2030

Group Awards By:

View Award Description

Leveraging single-cell co-culture and gene expression profiling to identify tumor antigen-specific T cells in oral cancer - Project Abstract Oral squamous cell carcinoma (OSCC) is an aggressive malignancy with a 5-year survival rate below 50%. Despite the moderate successes of immune checkpoint blockade, durable control is rare for OSCC, underscoring the need for improve immunotherapeutic approaches. Critical to immunotherapy efficacy is the specific targeting of tumor antigens by T cell receptors (TCRs). However, methods to identify and expand tumor-infiltrating lymphocytes (TILs) specific for OSCC antigens have not been established. To address this, we have developed two innovations in OSCC. First, we have optimized a high-throughput, single-cell co- culture system employing the Bruker Lightning platform. By studying single tumor cell-single TIL interactions, we can isolate individual tumor-killing T cells and identify the TCRs they carry. Second, we have performed single-cell RNA and TCR sequencing studies of OSCC and have identified a cytotoxic TIL sub-cluster with conserved gene expression patterns across patients suggestive of tumor-specificity. This cluster, which we have termed TProlif_Tox, can be identified across OSCCs and is enriched in markers for proliferation, T cell differentiation, cytotoxicity, and immune checkpoint blockade. Aim 1 leverages our single-cell co-culture platform to identify tumor antigen-specific TCRs. Patient-derived specimens will undergo both single-cell RNA/TCR sequencing as well as tumor and TIL culture. Patient- matched tumor and TILs will then be used for single-cell co-culture with identification of tumor antigen-specific TILs, and subsequent single-cell TCR sequencing. Tumor antigen-specific TCRs will then be projected back onto each patient’s initial single-cell RNA/TCR sequencing profile to identify in vivo gene expression profiles of tumor antigen-specific TILs. We hypothesize that these tumor antigen-specific TILs will be consistently identified within the TProlif_Tox cluster across OSCC patients. Aim 2 will translate tumor antigen-specific TIL identification into anti-tumor efficacy by engineering T cells with TCRs identified from the TProlif_Tox cluster (neoTCRs). We will then test the functional capabilities of these neoTCR T cells against autologous OSCC both in vitro and in vivo. Using Crispr-Cas9 editing, the endogenous T cell receptor (TRAC/TRBC1/TRBC2) will be disrupted in patient-matched circulating T cells with transfection and integration of neoTCRs. T cells carrying neoTCRs from the TProlif_Tox cluster can then be assessed for anti- tumor functionality through in vitro (co-culture with autologous malignant OSCC lines) and in vivo (humanized patient-derived xenograft) models. We anticipate that neoTCR-engineered T cells will demonstrate superior anti-tumor activity over control T cells, confirming the tumor antigen-specificity of the TProlif_Tox cluster. By refining the identification of tumor antigen-specific TILs and their TCRs, our study is poised to improve the precision and potency of immunotherapy for OSCC.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $390,000 )
2026	2026	THE MEDICAL COLLEGE OF WISCONSIN, INC.	8701 WATERTOWN PLANK RD	MILWAUKEE	WI	53226	MILWAUKEE	USA	Oral Diseases and Disorders Research	000	2	3/27/2026	NON-COMPETING CONTINUATION	$390,000
														Subtotal = $390,000

Issue Date FY: 2025 ( Subtotal = $390,000 )
2025	2025	THE MEDICAL COLLEGE OF WISCONSIN, INC.	8701 WATERTOWN PLANK RD	MILWAUKEE	WI	53226	MILWAUKEE	USA	Oral Diseases and Disorders Research	000	1	3/28/2025	NEW	$390,000
														Subtotal = $390,000

Grand Total All Awards = $780,000

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Leveraging single-cell co-culture and gene expression profiling to identify tumor antigen-specific T cells in oral cancer

Award Number: R01DE034360

ORGANIZATION: NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 04/01/2025

PERIOD OF PERFORMANCE END DATE: 03/31/2030

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer